All In Biotech

Drug Trial Radar · NCT05100862

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 799 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

799

Actual

Start

Mar 10, 2022

Primary completion

Jul 2028

Study completion Jun 2030

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Oct 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Conditions

  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma

Interventions

  • ZanubrutinibDrug

    Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.

  • RituximabDrug

    Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.

  • LenalidomideDrug

    Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.

  • ObinutuzumabDrug

    Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC)Time frame: Approximately 78 months

Locations

264 sites in 28 countries. Site status is shown where the registry gives one.

  • Ucsf Fresno University of California San Francisco Fresno

    Fresno, California

  • Kaiser Permanente Southern California

    Irvine, California

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • Los Angeles Cancer Network

    Los Angeles, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • UCLA Hematologyoncology

    Los Angeles, California

  • Scripps Health

    San Diego, California

  • Sharp Healthcare Sharp Memorial Hospital

    San Diego, California

  • Baptist Md Anderson Cancer Center

    Jacksonville, Florida

  • Ascension Sacred Heart

    Pensacola, Florida

  • Northwest Georgia Oncology Centers Marietta

    Marietta, Georgia

  • Cancer Care Specialists of Illinois

    OFallon, Illinois

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana

  • Mission Cancer and Blood

    Waukee, Iowa

  • Cotton Oneil Cancer Center

    Topeka, Kansas

  • Cancer Center of Kansas

    Wichita, Kansas

  • Baptist Health Lexington

    Lexington, Kentucky

  • Christus Highland Cancer Treatment Center

    Shreveport, Louisiana

  • Luminis Health Anne Arundel Medical Center

    Annapolis, Maryland

  • The University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Ascension St Agnes Hospital

    Baltimore, Maryland

  • American Oncology Partners of Maryland Pa

    Bethesda, Maryland

  • Henry Ford Hospital

    Detroit, Michigan

  • Corewell Health the Michigan Cancer Consortium

    Grand Rapids, Michigan

  • Hattiesburg Hematology and Oncology Clinic

    Hattiesburg, Mississippi

  • University of Missouri Hospital Ellis Fischel Cancer Center

    Columbia, Missouri

  • Oncology Hematology Associates

    Springfield, Missouri

  • St Vincent Frontier Cancer Center

    Billings, Montana

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Iyengar Hematology Oncology Medical Center Pa

    Bayonne, New Jersey

  • Summit Medical Group

    Florham Park, New Jersey

  • New York Cancer and Blood Specialists

    Shirley, New York

  • Suny Upstate Medical University

    Syracuse, New York

  • North Shore Hematology Oncology Associates Eccc Bronx

    The Bronx, New York

  • Optum Medical Care, Pc

    Westbury, New York

  • Levine Cancer Institute Wake Forest

    Charlotte, North Carolina

  • Oncology Hematology Care Clinical Trials, Llc

    Cincinnati, Ohio

  • Va Northeast Ohio Healthcare System

    Cleveland, Ohio

  • Toledo Clinic Cancer Center

    Toledo, Ohio

Showing 40 of 264 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.